Comparing Augmedix (OTCMKTS:AUGX) and Firefly Neuroscience (NASDAQ:AIFF)

Augmedix (OTCMKTS:AUGX) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Valuation and Earnings

This table compares Augmedix and Firefly Neuroscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Augmedix	$51.58 million	2.23	-$24.45 million	($0.43)	-5.47
Firefly Neuroscience	$1.14 million	15.20	-$19.88 million	($0.63)	-1.76

Firefly Neuroscience has lower revenue, but higher earnings than Augmedix. Augmedix is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

87.1% of Augmedix shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 11.0% of Augmedix shares are owned by insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Augmedix and Firefly Neuroscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Augmedix	0	0	0	0	0.00
Firefly Neuroscience	1	0	0	0	1.00

Profitability

This table compares Augmedix and Firefly Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Augmedix	-57.70%	-980.09%	-57.85%
Firefly Neuroscience	-506.23%	-106.16%	-80.85%

Risk & Volatility

Augmedix has a beta of -0.22, suggesting that its share price is 122% less volatile than the S&P 500. Comparatively, Firefly Neuroscience has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

About Augmedix

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

About Firefly Neuroscience

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.